Investor Overview

Corporate Profile
Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company focused on discovering and developing drugs to improve outcomes for patients with cancer. Verastem’s product candidates utilize a multi-faceted approach to treat cancer by reducing cancer stem cells, enhancing anti-tumor immunity, and modulating the local tumor microenvironment. The company’s most advanced clinical product candidates are the Focal Adhesion Kinase inhibitors, VS-6063 and VS-4718, and the dual PI3K/mTOR inhibitor, VS-5584.
Stock Quote
VSTM (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$1.36
Change (%) Stock is Up 0.06 (4.62%)
Volume154,668
Data as of 07/01/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News More >>
DateTitle 
06/14/16Verastem Announces Changes to its Board of Directors
BOSTON--(BUSINESS WIRE)--Jun. 14, 2016-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer, today announced several changes to the Company’s Board of Directors. Michael Kauffman, MD, PhD, who has served as a director since November 2012, will become Lead Director and Bruce J. Wendel will join the Board as an independent director. “Bruce is a proven leader whose experience building companies and brin... 
Printer Friendly Version
06/01/16Verastem to Present at Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--Jun. 1, 2016-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the following upcoming investor conferences: The Jefferies 2016 Healthcare Conference on Thursday, June 9 at 9:30 a.m. ET at the Grand Hyatt in New York City The JMP Securities Life Sciences Conference on Wednesday, June 22 at 10:0... 
Printer Friendly Version
05/09/16Verastem Reports First Quarter 2016 Financial Results
BOSTON--(BUSINESS WIRE)--May 9, 2016-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today reported financial results for the first quarter ended March 31, 2016, and also provided an overview of certain corporate developments. “To date in 2016, Verastem has announced two new clinical collaborations with world-class organizations, including Merck KGaA and Pfizer, and Washington University in St. ... 
Printer Friendly Version
05/03/16Verastem Announces the Presentation of Clinical Data at iMig 2016
- VS-6063 generally well tolerated; early signs of tumor reduction observed - - Results from Cohort 2 continue encouraging observations from Cohort 1 for single-agent VS-6063 in chemotherapy-naïve patients as a neoadjuvant therapy - BOSTON--(BUSINESS WIRE)--May 3, 2016-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the presentation of clinical data by Professor Raphae... 
Printer Friendly Version
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Verastem Inc posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.